ASC31 / Ascletis - LARVOL DELTA

Abstract Title: GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice (PRNewswire) - "Ascletis Presents...Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek 2025....The combination of ASC47 plus ASC31 resulted in a 44.8% reduction in weight compared to a 19.1% reduction for ASC31 monotherapy. This was a 134% greater reduction than ASC31 alone. The combination of ASC47 plus tirzepatide resulted in a 38.1% reduction in weight compared to a 20.4% reduction for tirzepatide alone."

Preclinical • Obesity

Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek 2025 (PRNewswire)

P1 data • Preclinical • Obesity

Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity (PRNewswire) - "Combination of a low dose of ASC47 with ASC31...resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (DIO) mouse model. Combination of a low dose of ASC47 with ASC31 demonstrated statistically significantly greater efficacy than a combination of a low dose of ASC47 with tirzepatide, 44.8% compared to 38.1%, respectively, in the DIO mouse model."

Preclinical • Obesity